Analgesics in Uzbekistan

October 2026

Analgesics in Uzbekistan in 2026 records significant momentum, supported by strong economic growth and sustained demand for affordable pain relief. Domestic manufacturers are gaining ground through lower-priced generics based on established molecules such as paracetamol, ibuprofen and diclofenac, while OTC reclassification is further directing consumers towards familiar single-ingredient options. Competition remains fragmented, with Isshaan Healthcare Pvt Ltd leading through Bolnol Plus, while established brands benefit from consumer trust and broad pharmacy distribution. Pressure on imported products from rising costs, tighter customs procedures and regulatory inspections is creating more favourable conditions for local production. Pharmacies remain the central route to purchase, reflecting the importance of immediate availability, product authenticity and pharmacist guidance on product selection and use. Looking ahead, tighter regulation is set to reshape competition as certification, pharmacovigilance and digital traceability become more important to market access and consumer confidence. Systemic analgesics is forecast to remain the largest area as Rx switching supports established single-ingredient products, while localisation is expected to intensify price competition. Companies combining recognised quality credentials, transparent supply chains and robust compliance capabilities are set to gain an advantage as regulatory requirements increase.

USD 1,195
Request More Information

Delivery:

Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).

This report comes in PDF with additional info in Excel included.

Overview:

Understand the latest market trends and future growth opportunities for the Analgesics industry in Uzbekistan with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.

Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.

If you're in the Analgesics industry in Uzbekistan, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.

The Analgesics in Uzbekistan report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volume and value sizes, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent research methodology, conducted in-country

This report answers:

  • What is the market size of Analgesics in Uzbekistan?
  • Which are the leading brands in Analgesics in Uzbekistan?
  • How are products distributed in Analgesics in Uzbekistan?
  • How has the regulatory and operating environment for Analgesics changed in Uzbekistan?
  • How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
  • How significant are wider health concerns and consumer awareness in determining sales?
  • Where is future growth expected to be most dynamic?

Key Data Insights

Affordable local generics gain ground as competition intensifies
Prescription switching strengthens demand for single-ingredient analgesics
Tighter standards increase the competitive value of certification and traceability
Chart 1 Value Sales 2021-2031
Chart 2 Value Sales by Category 2026
OTC reclassification expected to reinforce established single-ingredient analgesics
Localised pain relief and domestic production set to broaden competition
Certification and digital traceability poised to raise barriers to competition
Chart 1 Forecast Value Sales 2021-2031
Chart 2 Forecast Value Sales by Category 2026-2031
Bolnol Plus supports Isshaan Healthcare as importer pressures favour localisation
Chart 1 Company Shares 2026
Chart 2 Brand Shares 2026
Immediate access and professional advice sustain pharmacy leadership
Online pharmacies provide a supplementary route to analgesics
Chart 1 Retail Channels 2021-2026
Chart 1 Real GDP Growth 2021-2031
Chart 2 Inflation 2021-2031
Chart 1 Population 2021-2031
Chart 2 Population by Generation 2026
Chart 3 Consumer Expenditure 2021-2031

Country Reports Disclaimer

The following categories and subcategories are included:

Analgesics

      • Adult Acetaminophen
      • Adult Aspirin
      • Adult Combination Products - Analgesics
      • Adult Diclofenac
      • Adult Dipyrone
      • Adult Ibuprofen
      • Adult Ketoprofen
      • Adult Naproxen
      • Adult OTC Triptans
      • Paediatric Acetaminophen
      • Paediatric Aspirin
      • Paediatric Combination Products - Analgesics
      • Paediatric Dipyrone
      • Paediatric Ibuprofen
      • Paediatric Naproxen
      • Acetaminophen
      • Aspirin
      • Combination Products - Analgesics
      • Diclofenac
      • Dipyrone
      • Ibuprofen
      • Ketoprofen
      • Naproxen
      • OTC Triptans
  • Topical Analgesics/Anaesthetic

Analgesics

Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).

See all of our definitions
Share:

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This report originates from Passport, our Analgesics research and analysis database.

NEW REPORT GUARANTEE

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!